Research and Markets (http://www.researchandmarkets.com/research/g3cs7v/global_pulmonary) has announced the addition of the "Global Pulmonary Drug Delivery Systems Market 2015-2019" report to their offering.
The Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 8.9% over the period 2014-2019
Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity. Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices such as MDIs (or pMDIs), PDIs, and nebulizers. Drugs administered by this route are deposited in the respiratory tract via inertial impaction, gravitational sedimentation, and diffusion. The effective delivery of drugs via the pulmonary route requires an optimized combination of drug, its formulation, and device.
An increase in online marketing services is one major trend upcoming in the market. These services increase awareness regarding the products concerned, which increases the sales of these devices, thereby driving the market.
According to the report, an increase in the prevalence and incidence of respiratory diseases such as asthma and COPD is one of the major drivers of the market, and this is expected to increase the patient population requiring pulmonary drug delivery. Consequently, this is expected to increase the market revenue of pulmonary delivery systems. Any drug that can cater to these needs is expected to enhance the growth of the market during the forecast period
Further, the report states that intense market competition is one of the major challenges in the market. Medium and small-sized companies concentrate on a single product line in a specific geographic region and hence, have also intensified the market competition. The availability of generic drugs has also intensified the competition in the market.
Key Vendors
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Novartis
- Philips Healthcare
Key Topics Covered:
- Executive Summary
- List of Abbreviations
- Scope of the Report
- Market Research Methodology
- Introduction
- Market Landscape
- Market Segmentation by Product Type
- MDIs
- DPIs
- Nebulizers
- Geographical Segmentation
- Buying Criteria
- Market Growth Drivers
- Drivers and their Impact
- Market Challenges
- Impact of Drivers and Challenges
- Market Trends
- Trends and their Impact
- Vendor Landscape
- Key Vendor Analysis
For more information visit http://www.researchandmarkets.com/research/g3cs7v/global_pulmonary
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug
Delivery
